Recent Updates — MSLE
The United States Patent and Trademark Office issued U.S. Patent No. 12,747,245 covering composition of matter claims for forazapadin, Satellos’ lead clinical-stage drug candidate, as well as a broader class of AAK1 inhibitors. The patent provides intellectual property protection through September 6, 2044, with potential eligibility for Patent Term Extension following future U.S. marketing approval. Forazapadin is currently advancing in Phase 2 development for Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy. Satellos Bioscience Inc. operates as a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases.
Satellos Bioscience Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for forazapadin to treat facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate a Phase 2 clinical study in FSHD during the fourth quarter of 2026, evaluating safety and efficacy at 60 mg and 120 mg doses. Additionally, Satellos entered into a partnership with the FSHD Canada Foundation, which will provide up to US$5 million in non-dilutive financing through milestone payments over five quarters in exchange for capped revenue-sharing interest. This marks the second clinical indication for forazapadin, following ongoing development for Duchenne muscular dystrophy. Satellos Bioscience Inc. is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases.
Satellos Bioscience Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its drug candidate SAT-3247 for the treatment of Duchenne Muscular Dystrophy. This designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill unmet medical needs. Satellos Bioscience Inc. is a biotechnology company focused on developing therapies for neuromuscular diseases.